Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun 28;22(24):5505-11.
doi: 10.3748/wjg.v22.i24.5505.

Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update

Franco Scaldaferri  1 , Viviana Gerardi  1 , Francesca Mangiola  1 , Loris Riccardo Lopetuso  1 , Marco Pizzoferrato  1 , Valentina Petito  1 , Alfredo Papa  1 , Jovana Stojanovic  1 , Andrea Poscia  1 , Giovanni Cammarota  1 , Antonio Gasbarrini  1
Affiliations
Review

Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update

Franco Scaldaferri et al. World J Gastroenterol. .

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease, whose etiology is still unclear. Its pathogenesis involves an interaction between genetic factors, immune response and the "forgotten organ", Gut Microbiota. Several studies have been conducted to assess the role of antibiotics and probiotics as additional or alternative therapies for Ulcerative Colitis. Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug Mutaflor(®) (Ardeypharm GmbH, Herdecke, Germany and EcN, Cadigroup, In Italy) used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and UC. It is the only probiotic recommended in ECCO guidelines as effective alternative to mesalazine in maintenance of remission in UC patients. In this review we propose an update on the role of EcN 1917 in maintenance of remission in UC patients, including data about efficacy and safety. Further studies may be helpful for this subject to further the full use of potential of EcN.

Keywords: Escherichia coli Nissle; Inflammatory bowel disease; Metanalysis; Probiotic; Randomized trial; Ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure and mechanisms of action of Escherichia coli Nissle 1917. LPS: Lipopolysaccharide; IL-2: Interleukin-2; TNF: Tumor necrosis factor; IFN: Interferon.
Figure 2
Figure 2
Metanalysis on randomized controlled trials assessing role of Escherichia coli Nissle on maintenance of remission in ulcerative colitis.
See this image and copyright information in PMC

References

    1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407. - PubMed
    1. Scaldaferri F, Gerardi V, Lopetuso LR, Del Zompo F, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int. 2013;2013:435268. - PMC - PubMed
    1. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16:658–672. - PMC - PubMed
    1. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503–514. - PMC - PubMed
    1. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 2006;74:4075–4082. - PMC - PubMed

MeSH terms

Substances